ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Patient Perspectives on Bladder Cancer "
Episode Synopsis
CME credits: 0.50
Valid until: 21-02-2026
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
Valid until: 21-02-2026
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs). This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide the mBC patient perspective on AEs seen with newer immunotherapy.
More episodes of the podcast ReachMD CME
The Fifth Pillar? Closing the Gap in HFrEF
14/11/2025
In God we trust